The druggable genome and support for target identification and validation in drug development.

ABSTRACT: Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in drug development. Clinically relevant associations of variants in genes encoding drug targets model the effect of modifying the same targets pharmacologically. To delineate drug development (including repurposing) opportunities arising from this paradigm, we connected complex disease- and biomarker-associated loci from genome-wide association studies to an updated set of genes encoding druggable human proteins, to agents with bioactivity against these targets, and, where there were licensed drugs, to clinical indications. We used this set of genes to inform the design of a new ge

SUBMITTER: Finan C 

PROVIDER: S-EPMC6321762 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature